| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis |
2019-001762-14: Anti-inflammatory effects of Glycopyrronium Ontstekingsremmend effect Glycopyrronium |
|
|
| Not yet recruiting | 3 | 28 | Europe | QMF149, QVM149, Inhalation powder | University Medical Center Groningen, Novartis Pharma AG | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT05776927: A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. |
|
|
| Not yet recruiting | 3 | 304 | NA | QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149, Placebo to Salmeterol Xinafoate / Fluticasone Propionate, Run-In Medication, Rescue Medication, Concept 1 Device, Girohaler | Novartis Pharmaceuticals | Asthma | 03/26 | 08/27 | | |
| Completed | N/A | 434 | Europe | MF/IND/GLY plus sensor system, FDC therapy | Novartis Pharmaceuticals | Asthma | 01/23 | 01/23 | | |
NCT05274425: A 24-week rPMS Study in Real-world Setting for Enerzair |
|
|
| Recruiting | N/A | 600 | RoW | Enerzair 150/50/80 μg, Enerzair 150/50/160 μg | Novartis Pharmaceuticals | Asthma | 12/26 | 12/26 | | |